Literature DB >> 19820941

A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.

Wataru Ishii1, Dai Kishida, Ayako Suzuki, Yasuhiro Shimojima, Masayuki Matsuda, Yoshinobu Hoshii, Shu-Ichi Ikeda.   

Abstract

Systemic reactive amyloid A (AA) amyloidosis is one of the critical complications associated with rheumatoid arthritis (RA). Recently, there are several useful reports of anti-tumor necrosis factor therapy for RA-related systemic reactive AA amyloidosis patients. However, the time-kinetic transition between effective anti-inflammatory therapies and regression of AA amyloid deposits remains uncertain. Here, we report a RA patient with systemic reactive AA amyloidosis who was successfully treated with prednisolone and etanercept, showing marked regression of gastroduodenal mucosal amyloid deposits within only 4 months. This is the first case report of RA-related systemic reactive AA amyloidosis histopathologically demonstrating rapid regression of amyloid deposits on gastroduodenal mucosa after adequate suppression of the underlying inflammatory condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820941     DOI: 10.1007/s00296-009-1205-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Genotypes at SAA1 locus correlate with the clinical severity of AA-amyloidosis.

Authors:  M Moriguchi; C Terai; Y Koseki; H Kaneko; M Uesato; T Nishikawa; N Kamatani
Journal:  Amyloid       Date:  2001-06       Impact factor: 7.141

2.  Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  Ori Elkayam; Philip N Hawkins; Helen Lachmann; Michael Yaron; Dan Caspi
Journal:  Arthritis Rheum       Date:  2002-10

3.  Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Authors:  Antonio Fernández-Nebro; Eva Tomero; Vera Ortiz-Santamaría; María Carmen Castro; Alejandro Olivé; Manuel de Haro; Rosa García Portales; Rosa García-Vicuña; María Victoria González-Mari; Armando Laffón; Rosario García-Vicuña
Journal:  Am J Med       Date:  2005-05       Impact factor: 4.965

4.  Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis.

Authors:  M Moriguchi; C Terai; Y Koseki; M Uesato; A Nakajima; S Inada; M Nishinarita; S Uchida; A Nakajima; S Y Kim; C L Chen; N Kamatani
Journal:  Hum Genet       Date:  1999-10       Impact factor: 4.132

5.  Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Takashi Harada; Syuichi Murakami; Hisashi Hasegawa; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

Review 6.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

7.  Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis.

Authors:  Wataru Ishii; Masayuki Matsuda; Akinori Nakamura; Naoshi Nakamura; Akio Suzuki; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2003-09       Impact factor: 1.271

8.  Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide.

Authors:  Tomohisa Fushimi; Yasuhumi Takahashi; Yuichiro Kashima; Kazuhiro Fukushima; Wataru Ishii; Kazuma Kaneko; Masahide Yazaki; Akinori Nakamura; Takahiko Tokuda; Masayuki Matsuda; Ryo Furuya; Shu-Ichi Ikeda
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

9.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  4 in total

Review 1.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

2.  Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi; Serdal Ugurlu; Aycan Gokturk; Koray Tascilar; Huri Ozdogan
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

3.  Soluble tumour necrosis factor-alpha receptor improved the function, hypertrophy, and granular sparkling appearance of the left ventricular myocardium in systemic amyloid A amyloidosis: a case report.

Authors:  Sawa Miyagawa; Tadashi Miyamoto; Yukihito Sato
Journal:  Eur Heart J Case Rep       Date:  2020-03-16

4.  Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports.

Authors:  Makoto Fukuda; Naoki Sawa; Junichi Hoshino; Kenichi Ohashi; Miyazono Motoaki; Yoshifumi Ubara
Journal:  Clin Nephrol       Date:  2021-01       Impact factor: 0.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.